Loading clinical trials...

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NCT06975644•Zhejiang Provincial People's Hospital

View on ClinicalTrials.gov

Summary

Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)

Detailed Description

This study aims to prospectively evaluate the pathological complete response (pCR) rate in patients with early-stage triple-negative breast cancer (TNBC) receiving standard neoadjuvant chemotherapy combined with bemotuzumab.

Eligibility

Age

18 - 80 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1.Voluntarily agree to participate in the clinical study and sign the informed consent form.
•2.Female patients aged ≥18 years at the time of signing the informed consent form.
•3.Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to enrollment and agree to use a clinically recognized highly effective contraceptive method during the study and for 3 months after the last dose of the study drug.
•4.Adequate archival tumor tissue samples for HIM-type analysis (at least 15 unstained tumor biopsy slides from the most recent metastatic lesion; archival primary tumor samples from treatment-naïve patients are acceptable, or re-biopsied specimens may be submitted).
•5.Primary breast cancer meeting the following criteria:Histologically confirmed invasive breast cancer.Breast cancer staging (AJCC 8th edition): T1c-4, N0-2, M0.Histopathologically confirmed triple-negative invasive breast cancer (TNBC) meeting all criteria:HER2-negative: IHC 0/1+ or IHC 2+ with negative in situ hybridization (ISH).ER-negative: IHC \<1%.PR-negative: IHC \<1%.Unstained tumor sections must be submitted to the central laboratory as per the study protocol for biomarker validation.
•6.Willingness to undergo surgery if deemed eligible after neoadjuvant therapy.
•7.Adequate organ function as defined by protocol-specified laboratory thresholds.
•8.Eastern Cooperative Oncology Group (ECOG) performance status score ≤1 within 7 days prior to the first dose.

Exclusion Criteria

•1\. Pathological Staging a) Inflammatory breast cancer.b) Stage IV (metastatic) breast cancer, bilateral breast cancer, or multicentric breast cancer (defined as multifocal tumors involving more than one quadrant with lesions separated by ≥5 cm).
•2\. Tumor-Related Conditions a) Radiologic evidence of tumor invasion into major blood vessels or investigator-determined high risk of life-threatening hemorrhage due to impending vascular compromise.b) Uncontrolled or symptomatic hypercalcemia (\>1.5 mmol/L ionized calcium, \>12 mg/dL serum calcium, or albumin-corrected serum calcium \> upper limit of normal \[ULN\]); or symptomatic hypercalcemia requiring ongoing bisphosphonate therapy.c) Other severe concurrent illnesses interfering with treatment plans, including significant pulmonary conditions/diseases.
•3\. Prior/Concurrent Anticancer Therapies a) Previous or current systemic antitumor therapy for the current breast cancer (including chemotherapy, molecular targeted therapy, biologic therapy, or investigational agents).b) Participation in another clinical trial within 4 weeks prior to enrollment (3 months for monoclonal antibody trials) or planned participation during this study.c) Prior treatment with immune checkpoint inhibitors other than PD-1/PD-L1 monoclonal antibodies (e.g., CTLA-4 inhibitors) or anti-angiogenic agents (including monoclonal antibodies or TKIs).d) Administration of live/attenuated vaccines within 28 days before the first dose or anticipated vaccination during the study.
•4\. Medical History/Comorbidities a) Other malignancies within the past 5 years requiring systemic/local therapy (excluding cured carcinoma in situ, cervical intraepithelial neoplasia, basal/squamous skin cancer, or thyroid cancer).b) Major surgery within 28 days before the first dose (defined as requiring ≥3 weeks recovery) or palliative radiotherapy/ablation within 2 weeks.c) Known/suspected autoimmune diseases, except:Hypothyroidism managed with hormone replacement.Stable type 1 diabetes with controlled glycemia.d) Active viral hepatitis:HBV: HBsAg(+) or HBcAb(+) with HBV-DNA(+) (except those with HBV-DNA ≤2,500 copies/mL or 500 IU/mL after antiviral therapy).HCV: HCV-Ab(+) with HCV-RNA(+).Coinfection with HBV and HCV.e) HIV infection (HIV-Ab(+)).f) Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes, pulmonary fibrosis, acute pneumonitis).g) Severe infections:Hospital-required infections (e.g., bacteremia, pneumonia) within 4 weeks.Active CTCAE ≥Grade 2 infections requiring systemic antibiotics within 2 weeks.Unexplained fever \>38.5°C during screening (tumor-related fever permitted per investigator).Active tuberculosis within 1 year.h) Prior allogeneic bone marrow or solid organ transplantation.i) Peripheral neuropathy ≥Grade 2 (CTCAE v5.0).j) History of neurological/psychiatric disorders (e.g., epilepsy, dementia), drug/alcohol abuse.k) Significant cardiac disease:Heart failure (LVEF \<50%).High-risk arrhythmias (resting HR \>100 bpm, ventricular tachycardia, Mobitz II/third-degree AV block).Unstable angina requiring antianginal therapy.Clinically significant valvular disease.ECG-confirmed transmural myocardial infarction.Uncontrolled hypertension (systolic \>180 mmHg/diastolic \>100 mmHg).
•5\. Treatment-Related Exclusions a) Systemic immunostimulants (e.g., interferon, interleukin-2) within 4 weeks before the first dose.b) Systemic immunosuppressants (e.g., glucocorticoids, azathioprine) within 2 weeks, except:Topical/inhaled corticosteroids.Physiologic steroid replacement (≤10 mg/day prednisone equivalent).c) Hypersensitivity to study drug components or severe allergic reactions to monoclonal antibodies.
•6\. Pregnancy/Lactation Pregnant/lactating women or women of childbearing potential with positive baseline pregnancy tests or unwilling to use effective contraception.
•7\. Investigator Discretion Any condition deemed by the investigator to compromise protocol compliance or patient safety.

Key Dates

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Completion Date

December 31, 2026

Last Updated

May 22, 2025

Enrollment

ESTIMATED participants

Conditions

Triple-Negative Breast Cancer (TNBC)Neoadjuvant ChemotherapyChemotherapy Effects

Interventions

nab-paclitaxel, carboplatin, and bemotuzumab

DRUG

epirubicin, cyclophosphamide, and bemotuzumab

DRUG

Contacts

Hongchao Tang

CONTACT

+8613282037232 thc0571@live.com

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

NCT06155305

OrganoidsBreast Cancer+1 more

View study

RECRUITINGPHASE3

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

NCT06714604

Locally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Carcinoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Inclusion Criteria

Exclusion Criteria

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer